Abstract:What's new? While early detection of pancreatic cancer could significantly improve patient prognosis, clinically viable biomarkers are lacking. Here, the authors explored the of circulating microRNAs (miRNAs), which are highly stable and quantifiable from small amounts of plasma, for early detection of pancreatic cancer. Three miRNA targets identified in pre‐diagnostic plasma samples were associated with the development of pancreatic cancer within 5 years of sample collection. In addition, five other circulating miRNAs were associated with pancreatic cancer incidence specifically among patients who were diagnosed at age 65 or older. The findings highlight the potential value of circulating miRNAs for the early detection of pancreatic cancer. Early detection is critical for improving pancreatic cancer prognosis. Our study aims to identify circulating microRNAs (miRNAs) associated with pancreatic cancer risk. The two‐stage study used plasma samples collected ≤5 years prior to cancer diagnosis, from case–control studies nested in five prospective cohort studies. The discovery stage included 185 case–control pairs from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Replication stage samples comprised 277 pairs from Shanghai Women's Health Study/Shanghai Men's Health Study, Southern Community Cohort Study, and Multiethnic Cohort Study. Seven hundred and ninety‐eight miRNAs were measured using the NanoString nCounter Analysis System. Odds ratios (OR) and 95% confidence intervals (CI) for per 10% change in miRNAs in association with pancreatic cancer risk were derived from conditional logistic regression analysis in discovery and replication studies, separately, and then meta‐analyzed. Stratified analysis was conducted by age at diagnosis ( 2 years). In the discovery stage, 120 risk associated miRNAs were identified at p

Circulating microRNAs in association with pancreatic cancer risk within 5 years